Nancy Miller-Rich
Director/Board Member at ALDEYRA THERAPEUTICS, INC.
Net worth: - $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Todd Brady | M | 52 |
Helio Vision, Inc.
 Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 19 years |
| Theresa Janke | F | 49 | 11 years | |
| David Kirn | M | 62 | 11 years | |
| David I. Stirling | M | - |
BioTheryX, Inc.
 BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | 17 years |
| Robert Davis | M | 57 | 10 years | |
| Melvin Spigelman | M | 75 |
Global Alliance for TB Drug Development
 Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | 21 years |
| Richard Douglas | M | 71 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 8 years |
| Fariborz Kamal | M | 61 | 6 years | |
| Spencer Guthrie | M | 49 |
Attralus, Inc.
 Attralus, Inc. Pharmaceuticals: MajorHealth Technology Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA. | - |
| Bruce Greenberg | M | 56 | 5 years | |
| Philippe Drouet | M | - |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | 3 years |
| Gary Phillips | M | 58 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 15 years |
| Ahmad Doroudian | M | 63 |
Altum Pharmaceuticals, Inc.
 Altum Pharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Altum Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the clinical and commercial development of novel healthcare products for the treatment of women's gynecological neoplasia, autoimmune disorders, Hypercalcemia of Malignancy, Skeletal Related Events and Osteoporosis diseases. The company was founded in 2016 and is headquartered in Vancouver, Canada. | - |
| Scott Bizily | M | 52 | 3 years | |
| Jesse I. Treu | M | 76 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 9 years |
| David Norton | M | 72 |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | 11 years |
| Martin Joyce | M | 70 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 11 years |
| Noriyuki Kasahara | M | 62 | 2 years | |
| Mark Timney | M | 58 |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA. | 19 years |
| Ben Bronstein | M | 74 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 14 years |
| Shawn Tomasello | F | 65 | 4 years | |
| Rahul Kakkar | M | 49 |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA. | 3 years |
| John Milligan | M | 63 | 4 years | |
| Diantha Duvall | F | 52 |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | 10 years |
| Dean Eliott | M | - |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 8 years |
| Jared M. Freedberg | M | 55 | 3 years | |
| Jonathan Wall | M | - |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA. | - |
| Julian Pei | M | - | - | |
| Robert Kim | M | 63 | 2 years | |
| James A. Gow | M | - | 4 years | |
| Jacob Chacko | M | 45 | 5 years | |
| Neal Walker | M | 54 | 11 years | |
| Shane Cooke | M | 61 | 5 years | |
| Jake Bauer | M | 45 |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA. | 3 years |
| Pamela Craig | F | 67 | 9 years | |
| Myles Lee | M | 70 | 7 years | |
| Shalini Sharp | F | 49 |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | 9 years |
| Alexander Denner | M | 54 |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA. | 3 years |
| Susannah Gray | F | 63 | 4 years | |
| Charles Theuer | M | 60 | 8 years | |
| Paul Rothman | M | 66 | 9 years | |
| Peter N. Crnkovich | M | - |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | 5 years |
| Corey Goodman | M | 72 |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA. | - |
| Uneek Mehra | M | 51 | 1 years | |
| Carol Bowden | F | - | 10 years | |
| Kyle W. H. Chan | M | - |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | 17 years |
| Andre Musto | M | - | 10 years | |
| Brooke Hinkson | F | - | 9 years | |
| An Song | M | - | 3 years | |
| Jeffrey Edwards | M | 64 |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | 5 years |
| Paul Sekhri | M | 65 |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | - |
| Stefano Pasi | M | - | 1 years | |
| Francesco Balestrieri | M | 55 | 1 years | |
| Richard Gaster | M | 40 |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA. | 4 years |
| Rajeev Dadoo | M | 54 |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | - |
| Mitchell Warren | M | - |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | - |
| Ali Ardakani | M | - |
Altum Pharmaceuticals, Inc.
Altum Pharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Altum Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the clinical and commercial development of novel healthcare products for the treatment of women's gynecological neoplasia, autoimmune disorders, Hypercalcemia of Malignancy, Skeletal Related Events and Osteoporosis diseases. The company was founded in 2016 and is headquartered in Vancouver, Canada. | - |
| Peter Dannenbaum | M | - | 7 years | |
| Sangita Reddy | M | 61 |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | 3 years |
| Ariel Pablos-Méndez | M | - |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | - |
| Dean Li | M | 62 | 7 years | |
| Mario Raviglione | M | - |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | 9 years |
| Andrew Saik | M | 54 | 3 years | |
| Willo Brock | M | - |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | 10 years |
| Louis J. DeGennaro | M | - |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | - |
| Jane Griffiths | M | 69 |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | 4 years |
| Vassiliki Economides | F | 44 |
Altum Pharmaceuticals, Inc.
Altum Pharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Altum Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the clinical and commercial development of novel healthcare products for the treatment of women's gynecological neoplasia, autoimmune disorders, Hypercalcemia of Malignancy, Skeletal Related Events and Osteoporosis diseases. The company was founded in 2016 and is headquartered in Vancouver, Canada. | - |
| Kim Schwartz | F | - |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | 2 years |
| Michele Cera | F | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Alan Ralph | M | 55 | 19 years | |
| Mark Pruzanski | M | 56 | 21 years | |
| Charles Kidder | M | 79 |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | 12 years |
| Joseph Romanelli | M | 50 |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | 19 years |
| Paolo Fundarò | M | 50 | 17 years | |
| Christopher Corbin | M | 69 | 17 years | |
| David Schaffer | M | 53 | 9 years | |
| Keith Gottesdiener | M | 70 |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | 7 years |
| Richard Kogan | M | 81 |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | 21 years |
| Michael Gannon | M | - | 3 years | |
| Jean-Marie Canan | M | 68 | 5 years | |
| Robert Iannone | M | 57 | 6 years | |
| Larry G. Edwards | M | 52 | 15 years | |
| Joshua Reed | M | 51 | 4 years | |
| Laura Sepp-Lorenzino | M | 63 | 15 years | |
| Teri Loxam | F | 52 | 4 years | |
| Natarajan Sethuraman | M | 62 | 10 years | |
| Dagmar Rosa-Bjorkeson | F | 60 | 2 years | |
| Sean Coyle | M | 51 | 8 years | |
| Mark Vignola | M | 47 | 4 years | |
| John Noseworthy | M | 71 | - | |
| Gerardus Wilhelmus van Odijk | M | 67 | 5 years | |
| Philip Toomey | M | 70 | 11 years | |
| Chris Brinsmead | M | 64 | 10 years | |
| Ryan Sullivan | M | 48 | 2 years | |
| Jim Suddendorf | M | - |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | 12 years |
| Liam Michael FitzGerald | M | 58 | 23 years | |
| Peter Chambré | M | 68 | - | |
| Glenn Sblendorio | M | 68 | 9 years | |
| Daniel Bradbury | M | 62 | 7 years | |
| Sheila Ranganath | F | - | 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 71 | 71.00% |
| Ireland | 11 | 11.00% |
| Canada | 3 | 3.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Nancy Miller-Rich
- Personal Network
